Drug Profile


Latest Information Update: 17 Feb 2003

Price : $50

At a glance

  • Originator Unknown
  • Developer BioPulse International [CEASED]
  • Class Antineoplastics
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 17 Feb 2003 Discontinued - Clinical-Phase-Unknown for Cancer in Mexico (unspecified route)
  • 28 Sep 2000 New profile
  • 28 Sep 2000 Investigation in Cancer in Mexico (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top